BlinkLab Adds Clinical Site For Autism Diagnostic Test Pivotal US Regulatory Trial, Shares Fall 4%

MT Newswires Live
02/12

BlinkLab (ASX:BB1) added Drexel University as a clinical site for its pivotal US regulatory trial for its BlinkLab Dx 1 autism diagnostic test, according to a Thursday Australian bourse filing.

Drexel University became the ninth institution to participate in the FDA 510(k) registrational trial across the US. The study will enroll around 528 children, between the ages of 2 and 11 years.

Its shares fell 4% in recent trading on Thursday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10